Moderna raises its revenue outlook — but all eyes are on what happens next with its cancer vaccine
Summary
Moderna shares experienced a notable increase in value following an updated financial projection from the biotechnology firm. Management announced expectations for significant revenue growth over the next couple of years, leading to the positive market reaction.
The company lifted its revenue outlook for the year, saying it expects revenue to grow as much as 25% in 2026.
Source: Read the full story at MarketWatch.com - Top Stories
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.